NASDAQ:VTVT - vTv Therapeutics Stock Price, Forecast & News

vTv Therapeutics' stock was trading at $2.43 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, VTVT stock has decreased by 16.9% and is now trading at $2.02. View which stocks have been mosted impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for vTv Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for vTv Therapeutics.

vTv Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, May 6th 2020. View our earnings forecast for vTv Therapeutics.

vTv Therapeutics Inc (NASDAQ:VTVT) released its quarterly earnings data on Thursday, November, 8th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.12) by $0.06. The biotechnology company earned $3.38 million during the quarter, compared to analyst estimates of $2.06 million. View vTv Therapeutics' earnings history.

2 brokers have issued 12 month price objectives for vTv Therapeutics' stock. Their forecasts range from $6.00 to $8.00. On average, they expect vTv Therapeutics' stock price to reach $7.00 in the next year. This suggests a possible upside of 246.5% from the stock's current price. View analysts' price targets for vTv Therapeutics.

News stories about VTVT stock have trended very negative this week, according to InfoTrie Sentiment. The research firm scores the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. vTv Therapeutics earned a media sentiment score of -3.8 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an impact on the stock's share price in the near term. View the latest news aboutvTv Therapeutics.

Some companies that are related to vTv Therapeutics include Vanda Pharmaceuticals (VNDA), Vectura Group (VEGPF), INDIVIOR PLC/S (INVVY), Emisphere Technologies (EMIS), Assembly Biosciences (ASMB), Akero Therapeutics (AKRO), Sinovac Biotech (SVA), ANI Pharmaceuticals (ANIP), G1 Therapeutics (GTHX), BioXcel Therapeutics (BTAI), AC Immune (ACIU), Atreca (BCEL), CytoDyn (CYDY), Kura Oncology (KURA) and RAPT Therapeutics (RAPT).

Based on aggregate information from My MarketBeat watchlists, some companies that other vTv Therapeutics investors own include Agile Therapeutics (AGRX), Crispr Therapeutics (CRSP), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Advanced Micro Devices (AMD), Amarin (AMRN), Opko Health (OPK), Inovio Pharmaceuticals (INO), Anavex Life Sciences (AVXL) and Micron Technology (MU).

(VTVT) raised $125 million in an initial public offering on Thursday, July 30th 2015. The company issued 7,800,000 shares at $15.00-$17.00 per share. Piper Jaffray and Stifel acted as the underwriters for the IPO and Canaccord Genuity and Janney Montgomery Scott were co-managers.

vTv Therapeutics trades on the NASDAQ under the ticker symbol "VTVT."

vTv Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Bank of America Corp DE (0.24%), Barclays PLC (0.24%) and Renaissance Technologies LLC (0.07%). Company insiders that own vTv Therapeutics stock include Hersh Kozlov, Paul G Savas and Ronald O Perelman. View institutional ownership trends for vTv Therapeutics.

VTVT stock was bought by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Barclays PLC, and Renaissance Technologies LLC. Company insiders that have bought vTv Therapeutics stock in the last two years include Hersh Kozlov, Paul G Savas, and Ronald O Perelman. View insider buying and selling activity for vTv Therapeutics.

Shares of VTVT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of VTVT stock can currently be purchased for approximately $2.02.

vTv Therapeutics has a market capitalization of $131.83 million and generates $2.76 million in revenue each year. The biotechnology company earns $-13,040,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. vTv Therapeutics employs 52 workers across the globe. View additional information about vTv Therapeutics.

The official website for vTv Therapeutics is http://www.vtvtherapeutics.com/.

vTv Therapeutics' mailing address is 3980 PREMIER DR SUITE 310, HIGH POINT NC, 27265. The biotechnology company can be reached via phone at 336-841-0300 or via email at [email protected]